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Abstract
Background Brain-derived neurotrophic factor (BDNF) is
involved in the survival and function of midbrain DA
neurons. BDNF action is mediated by the TrkB receptor–
tyrosine kinase, and both BDNF and TrkB transcripts are
widely expressed in the rat mesolimbic pathway, including
the nucleus accumbens (NAc) and the ventral tegmentum
area (VTA).
Objective BDNF was previously shown to be involved in
cocaine reward and relapse, as assessed in rat models. The
goal of this study is to explore the role of BDNF and TrkB
in the rat nucleus accumbens (NAc) in cocaine-induced
psychomotor sensitization and in conditioned-place prefer-
ence acquisition, expression, and reinstatement.
Materials and methods In vivo genetic manipulations of
BDNF and TrkB were performed using a lentiviral gene
delivery approach to over-express these genes in the NAc
and siRNA-based technology to locally knockdown gene
expression. Behavioral experiments consisted of locomotor
activity monitoring or cocaine-induced conditioned-place
preference (CPP).
Results BDNF and/or its receptor TrkB in the NAc enhance
drug-induced locomotor activity and induce sensitization
in rats. Furthermore, LV-BDNF- and LV-TrkB-treated rats
display enhanced cocaine-induced CPP, delayed CPP-
extinction upon repeated measurements, and increased
CPP reinstatement. In contrast, expression of TrkT1
(truncated form of TrkB, acting as a dominant negative)
inhibits these behavioral changes. This inhibition is also
observed when rats are fed doxycycline (to block lentivirus-
mediated gene expression) or when injected with siRNAs-
expressing lentiviruses against TrkB. In addition, we
investigate the establishment, maintenance, extinction, and
reinstatement of cocaine-induced CPP. We show that BDNF
and TrkB-induced CPP takes place during the learning
period (conditioning), whereas extinction leads to the loss
of CPP. Extinction is delayed when rats are injected LV-
BDNF or LV-TrkB, and in turn, priming injections of
2 mg/kg of cocaine reinstates it.
Conclusions These results demonstrate the crucial function
of BDNF—through its receptor TrkB—in the enhancement
of locomotor activity, sensitization, conditioned-place pre-
ference, CPP-reinstatement, and rewarding effects of
cocaine in the mesolimbic dopaminergic pathway.
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GFP green fluorescent protein
HEK293T human embryonic kidney 293T cells
NAc nucleus accumbens
NGF nerve growth factor
qRT-PCR quantitative real-time polymerase chain
reaction
shRNA short hairpin RNA
siRNA small interference RNA
TH tyrosine hydroxylase
Trk receptor–tyrosine kinase
uPA urokinase-type plasminogen activator
VTA ventral tegmental area
Introduction
Psychostimulant exposure induces transient increases in
brain-derived neurotrophic factor (BDNF) signaling and
increases expression of its receptor TrkB in the dorsal
striatum (Meredith et al. 2002; Meredith and Steiner 2006).
Cocaine induces TrkB-mediated signaling in the nucleus
accumbens (NAc; Berhow et al. 1995). Furthermore, acute
cocaine administration increases striatal expression of a
specific BDNF4 splice variant up to fivefold, not observed
upon chronic administration, suggesting a role of specific
BDNF promoter regions and regulatory sequences in
stimulatory-induced alterations in BDNF expression (Liu
et al. 2006; Pu et al. 2006). Administration of BDNF
prevents biochemical and morphological changes asso-
ciated with chronically administered cocaine and morphine,
whose rewarding effects are mediated by the activation of
dopamine neurons (DA) in the nucleus accumbens (NAc).
BDNF has been implicated in mediating cue-induced
cocaine craving and was found to enhance responding for
cues associated with natural rewards (Bolaños and Nestler
2004), possibly through sustained increases in BDNF levels
within the VTA, NAc, and amygdala (Grimm et al. 2003).
Furthermore, BDNF injections into the VTA or NAc enhances
cocaine sensitization and conditioned reinforcement (Horger
et al. 1999). In addition, BDNF is responsible for inducing
normal expression of D3 dopamine receptors in the NAc
shell (Guillin et al. 2001), regulating cellular signaling path-
ways activated by cocaine, and preventing drug-induced
morphological changes in the DA system. Recent studies,
using localized inducible BDNF knockout in mice, showed
that BDNF originating from NAc neurons was necessary for
maintaining increased cocaine self-administration. These
findings suggest that dynamic induction and release of
BDNF from NAc neurons during cocaine use promotes the
development and persistence of addictive behavior (Graham
et al. 2007). In addition, BDNF and NT3 potently influence
behavioral sensitization to cocaine and the regulation of
dopaminergic transmission to the NAc (Martin-Iverson and
Altar 1996; Pierce et al. 1999). Behavioral studies have
shown that heterozygous BDNF knockout throughout the
brain delays the development of cocaine sensitization
(Horger et al. 1999; Messer et al. 2000) and attenuates the
rewarding effects of cocaine in conditioned-place preference
(Hall et al. 2003). As BDNF is implicated in synaptic
plasticity, primarily through its receptor TrkB (Bibel and
Barde 2000; Bonhoeffer 1996; Kryl et al. 1999; Patapoutian
and Reichardt 2001; Thoenen 2000), BDNF-mediated
neuroadaptations in mesolimbic areas are therefore probably
involved in the persistent cocaine seeking induced by
exposure to drug cues after withdrawal (Lu et al. 2004).
In this report, we evaluate the role of BDNF and its
receptors TrkB or TrkT1 in behavioral adaptations to
cocaine by means of lentivirus-mediated gene transfer.
Lentiviral vectors are known to maintain ectopic gene
expression for a long period of time and to infect neurons
efficiently. Therefore, our approach aims at locally modi-
fying gene expression levels, overexpressing or silencing
BDNF or TrkB in the NAc. Lentiviruses expressing BDNF,
TrkB, or TrkT1 or lentiviruses expressing TrkB-specific
siRNAs were stereotaxically injected into the NAc, and
behavioral changes in response to cocaine were monitored.
We show that BDNF and TrkB activation significantly con-
tributes to cocaine-induced locomotor activity and conditioned-
place preference (CPP), delayed extinction, and increased CPP
reinstatement, and we discuss the mechanisms implicated in
this adaptation.
Materials and methods
Lentiviral construction
LV-BDNF
The rat BDNF cDNA was amplified by reverse transcrip-
tion using specific primers and Superscript II RNaseH
Reverse Transcriptase according to the manufacture’s
instructions (Invitrogen, Switzerland). The total RNA was
prepared from rat NAc of cocaine-treated animals. The
cDNAwas then polymerase chain reaction (PCR) amplified
and tagged with the two following primers: 5′-CGC GGG
ATC CAT GAC CAT CCT TTT CCT T-3′ and 5′-GCC
GCT CGA GCT ACA GGT CCT CCT CTG AGA TCA
GCT TCT GTC TTC CCC TTT TAAT-3′ (restriction sites
are underlined). The forward primer contains a BamHI
restriction site followed by the 5′ rat BDNF cDNA-specific
sequence; the reverse primer contains the 3′ rat BDNF
cDNA-specific sequence, a Myc tag (sequence in bold), a
stop codon, and an XhoI restriction site.
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LV-TrkB and LV-TrkT1
The rat TrkB and its truncated form TrkT1 were amplified
by PCR using specific primers and plasmids holding these
cDNAs (pEF/BOS-TrkB-Flag and pEF/BOS-TrkT1-Flag,
respectively, kindly provided by Prof. E. Castren, University
of Helsinki, Finland). The forward primer used for both
genes was 5′-CGC GGG ATC CA TGT CGC CCT GGC
CGA GG-3′. The TrkB-Flag reverse primer: 5′-GCC GCT
CGA GCT AGC CTA GGA TGT CCA G-3′. The TrkT1
reverse primer: 5′-GCC GCT CGA GCT ACC CAT CCA
GGG GGA T-3′. The forward primer contains a BamHI
restriction site followed by the 5′ rat TrkB/T1 cDNA-specific
sequence, the reverse primers an XhoI restriction site
(restriction sites are underlined). The PCR products (BDNF,
TrkB and TrkT1) were digested with BamHI/XhoI and
cloned into pTK431 previously digested with the same
enzymes. The resulting vectors (pTK431-BDNF, pTK431-
TrkB and pTK431-TrkT1) were then sequenced to check for
mutation absence, amplified, and used for lentiviral produc-
tion as described below. The green fluorescent protein (GFP)
expression vector pTK433 (Bahi et al. 2004a, b, 2005a, b,
2006) was used as a control vector.
LV-siRNAs
To knockdown TrkB and TrkT1 expression in vitro and in
vivo, three targets were designed according to the rat TrkB
mRNA sequence. The following targets within the TrkB
sequence were selected, based on Hannon’s design criterion
(http://katahdin.cshl.org:9331/RNAi/html/rnai.html): first
target, bp 5–27; second target, bp 2,438–2,460; third target,
bp 1,500–1,522. To each oligo, an XhoI restriction site was
added at 3′ and a U6-3′-specific 15-mer at 5′. Using the
pSilencer 1.0-U6 (Ambion, UK) as a template and a U6
promoter-specific forward primer containing a BamHI
restriction site (GCG GAT CCC GCT CTA GAA CTA
GTG C), each siRNA target was added to the mouse U6
promoter by PCR. The PCR conditions were highly stringent
to avoid mutations within the targets. The following PCR
program was performed: 120 s at 94°C (initial denaturation)
followed by 94°C for 45 s, 64°C for 45 s, and 72°C for 45 s,
repeated for 35 cycles. The PCR reaction contained 4%
dimethyl sulfoxide (Sigma, Switzerland). The PCR product
was digested with BamHI and XhoI, cloned into similar sites
into pTK431 and sequenced to verify the integrity of each
construct.
The vector plasmids (either pTK433-GFP, pTK431-
BDNF, pTK431-TrkB, pTK431-TrkT1, or pTK431-
U6-Trk-siRNAs), together with the packaging construct
plasmid pΔNRF and the envelope plasmid pMDG-VSV-G,
were co-transfected into HEK293T cells to produce the
viral particles (Bahi et al. 2004a, b, 2005a, b, 2006). The
viral titers were determined by p24 antigen measurements
(KPL, USA) after concentration by mean of ultracentrifu-
gation. For the in vivo experiments, the different viral
stocks were matched for viral particle content and used at
0.2 mg/mL of p24.
In vitro BDNF, TrkB, and TrkT1 transcript
uantification assays
The efficiency of the LV-BDNF, LV-TrkB, and LV-TrkT1
was tested in vitro by infection of HEK293T cells.
HEK293T cells were plated at 1×105 per well in six-well
plates. The next day, lentivirus stocks were mixed with
10 μg/mL Polybrene (Sigma, Switzerland), incubated for
30 min at room temperature, added to the cells, and
incubated at 37°C with or without 30 ng/mL doxycycline
(Sigma, Switzerland). After 48 h, the medium was replaced
with normal growth medium supplemented with 10% fetal
calf serum and 1× penicillin/streptomycin (with or without
30 ng/mL doxycycline), and cells were left for a further
48 h. Cells were then collected and used for total RNA
isolation (for real time PCR). Infections with the different
lentiviruses were carried out as follows:
(1) In vitro doxycycline regulation: cells were infected
using 0, 2, 4, or 8 μL of the LV-BDNF, LV-TrkB, or
LV-TrkT1 stock. In addition, each well was co-
infected with 4 μL of LV-CD81 and 4 μL of LV-uPA
(Bahi et al. 2004a, b, 2005a, b, 2006), doxycycline
regulatable lentiviruses used as controls under each
condition. One part of the cells was incubated in the
presence of 30 ng/mL doxycycline and the other part
without doxycycline.
(2) In vitro silencing of TrkB/TrkT1: cells were infected
with 4 μL each of LV-TrkB, LV-TrkT1, LV-CD81, and
LV-uPA stocks, either alone or together with 2 μL of
either, respectively, LV-Trk-siRNA1, LV-Trk-siRNA2,
or LV-Trk-siRNA3, or with 2 μL of all three targets
together (mix of LV-Trk-siRNA1, LV-Trk-siRNA2,
and LV-Trk-siRNA3). After 96 h, cells were collected
for RNA extraction, mRNA was quantified by quan-
titative real-time (qRT)-PCR and normalized against
GAPDH (Bahi et al. 2005a, b).
RT-PCR and quantification of BDNF, TrkB,
and TrkT1 transcripts expressed in the NAc
For qRT-PCR, primer sets for rat, BDNF, TrkB, TrkT1,
GAPDH, beta-actin, uPA, and CD81 were designed to
amplify 100- to 200-bp products, using PRIMER3 software:
(http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi).
3
ht
tp
://
do
c.
re
ro
.c
h
The following specific primer pairs were used: BDNF: 5′-
GGT TCG AGA GGT CTG ACG AC-3′ and 5′-CAA AGG
CAC TTG ACT GCT GA-3′; TrkB: 5′-CCT CGT CGG
AGA AGA TCA AG-3′ and 5′-CGT GGT ACT CCG TGT
GAT GT-3′; TrkT1: 5′-AGC AGC CCT GGT ATC AGC
TA-3′; GAPDH: 5′-ATG ACT CTA CCC ACG GCA AG-3′
and 5′-CAT ACT CAG CAC CAG CAT CAC-3′; beta-actin:
5′-AGC CAT GTA CGTAGC CAT CC-3′ and 5′-CTC TCA
GCT GTG GTG GTG AA-3′; uPA: 5′-CAG ATC CGATGC
TCT TAG CC-3′ and 5′-TAG AGC CTT CTG GCC ACA
CT-3′; CD81: 5′-TGATCC TGT TTG CCT GTG AG-3′ and
5′-CAG TTG AGC GTC TCA TGG AA-3′. GAPDH was
used as endogenous control for normalization. Total RNA
was extracted from the HEK293T cells (for in vitro
quantification) and from the NAc of brains of cocaine-
treated rats (for in vivo quantification) using TRIzol Reagent
(Invitrogen, Switzerland) including an RNase-free DNase
step according to the manufacturer’s instructions. RNA was
quantified by spectrophotometry and its integrity verified by
agarose gel electrophoresis as visualized with ethidium
bromide staining. First-strand cDNA was generated from
2 μg of total RNA and Oligo(dT12–18) primer with the
Superscript II RNaseH Reverse Transcriptase kit according
to the manufacturer’s instructions (Invitrogen, Switzerland)
in a total volume of 20 μL. The reaction product was used
for quantitative RT-PCR using the RT-PCR iCycler
according to the manufacturer’s instructions (Bio-Rad,
Switzerland). Briefly, cDNA preparation (5 μL), 0.5 μM
of forward and reverse primers, and 10 μL of IQ SYBR
Green Supermix (Bio-Rad) in a total volume of 20 μL
was applied, and PCR was performed as follows: 3 min
at 95°C (initial denaturation), 20°C/s temperature transi-
tion rate up to 95°C for 45 s then 45 s at 64°C, repeated
40 times (amplification). The PCR reaction was evaluated
by melting curve analysis and by checking the PCR
products on 2% agarose gel.
The PCR cycle number at which each assay target
reached the threshold detection line was determined
(“threshold cycles”, Ct value). The Ct of each gene was
normalized against that of GAPDH. To determine the
linearity and detection limit of the assay, cDNA samples
were amplified for successive tenfold dilutions in a series of
RT-PCRs, using duplicate assays on each dilution, so that
the correlation coefficient could be calculated from the
standard curve of Ct values. Comparisons were made
between cocaine and saline groups, and significance was
calculated using two-tailed Student’s t test, and the level of
statistical significance was set at p<0.05. Data were
expressed as mean±SEM. The ΔCt for each candidate
was calculated as ΔCt=[Ct(candidate)−Ct(GAPDH)]. The
relative abundance of each target in each protocol can be
calculated as the ratio between treated and untreated
samples (Bahi et al. 2004a, b, 2005a, b, 2006).
Animal handling and drug delivery protocols
Animals used in these experiments were male Wistar rats
weighing 225–250 g. All animal experiments were carried
out in accordance with the guidelines and regulations for
Animal Experimentation, BAG, Bern, Switzerland. The
animals were housed three per cage in clear plastic cages
with wire grid lids. Access to food and water was unrestricted.
The rats were kept in the animal facility maintained on a
12-h light/12-h dark cycle (lights off at 7 A.M.).
Stereotaxic surgery Stereotaxic surgery and injection of the
lentiviral vectors were performed according to previous
publications (Bahi et al. 2004a, b, 2005a, b). Briefly, rats
(n=9 per group) were bilaterally injected into the NAc with
a total of 4 μL of concentrated lentiviral stock (0.2 mg/mL
of p24, corresponding to 8×109 IU/mL). Seven groups (n=
9 per group) were prepared as follows: LV-GFP; LV-BDNF;
LV-TrkB; LV-BDNF+LV-TrkB; LV-TrkT1; LV-TrkB+
LV-siRNAs; LV-BDNF+LV-TrkB+LV-Trk-siRNAs. All
injections were performed bilaterally at the following co-
ordinates, as calculated from the bregma and the dura
mera: anterior +1.4, lateral ±1.6, ventral −6.8 (Paxinos and
Watson 1998). After surgery, animals were left for recovery
for 7 days.
Experiment 1: LV–BDNF- and LV-TrkB-induced
locomotor activity upon cocaine treatment
One week after surgery, locomotor activity was monitored
in MED-OFA-RS cages (MED Associates, USA) during the
dark cycle in daily sessions over 15 days, according to
previously published procedures (Bahi et al. 2004a, b,
2005a, b, 2006). The rat was injected with 0.9% saline
solution and placed into the activity-monitoring cage for a
30-min baseline. After a 30-min period, the session
automatically paused, and during this interval, each subject
received cocaine–HCl (15 mg/kg, i.p.) and was then placed
back into the locomotor activity-monitoring cage for a
further 60 min. Animals were fed 5% sucrose in drinking
water for 5 days (Session A, days 1–5), then 0.02%
doxycycline and 5% sucrose in water for a further 7 days
(Session B, days 6–12), then again 5% sucrose for seven
more days (Session C, days 13–19).
At the end of each behavioral session, three animals
were killed by decapitation to assess the efficiency of the
BDNF, TrkB, and TrkT1 mRNAs expression in vivo. Brains
(n=3) were dissected out, the NAc region was isolated, and
total RNAwas extracted using TRIzol Reagent according to
the manufacturer’s guidance (Invitrogen, Switzerland). The
isolated total RNA was used for transcript quantification by
means of qRT-PCR.
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Experiment 2: Cocaine-induced conditioned-place
preference
Conditioned-place preference was performed as previously
described (Mueller and Stewart 2000). Briefly, in the
preconditioning period, the rat was allowed to move freely
between two boxes (consisting of either wire grid or mesh
floor) daily for 20 min for 3 days (days 1–3). On day 3, the
time spent in each chamber was monitored and used to
assess unconditioned preferences. Before conditioning, the
rats were divided into two groups (n=18 per group). One
group of rats received water supplemented with 5% sucrose
and 0.02% doxycycline in drinking water during condi-
tioning, the other group was fed only 5% sucrose. During
the conditioning phase, the rat was injected with cocaine
(5 or 20 mg/kg, i.p.; n=9 per group) on days 4, 6, and 8 and
immediately confined into the mesh floor box for 20 min.
On days 5, 7, and 9, the rat was injected with saline (1 ml/kg)
and placed into the wire grid floor chamber for 20 min.
During the conditioning phase, chambers were blocked by a
guillotine door and were never communicating. On day 10,
the post-conditioning “CPP” test was performed without
drug treatment. Rats were placed between the two chambers
with the guillotine door removed and allowed free access to
the entire set-up. The time spent in each chamber was
measured for 20 min. Drug-induced-place preference was
expressed by post versus pre, which was calculated as:
[(post-value)−(pre-value)], where post- and pre-values
were the difference in time spent at the drug-conditioning
site during post-conditioning and preconditioning periods,
respectively.
Experiment 3: extinction by repeated testing
After conditioning and following the initial CPP test, rats
underwent 20 min tests daily for 20 days. No injections
were performed during this prolonged period of withdrawal
from cocaine.
Experiment 4: reinstatement by priming using low
dose of cocaine
The day after the last extinction trial, rats received a
priming injection of saline (1 ml/kg), followed 24 h later,
by a priming injection of cocaine (2 mg/kg, i.p.) and were
placed between the two boxes with access to the entire set
up for 20 min.
Experiment 5: maintenance of the CPP
After CPP, test rats (n=9 per group) underwent a 5-week
period of withdrawal from cocaine. During this time,
animals were not injected and not tested but were kept in
their home cages. After this period, rats were placed in a set
up between the two boxes with free access to both
compartments and measured for 20 min.
Immunohistochemistry
Brain sections were prepared for immunohistochemistry
according to previously published procedures (Bahi et al.
2004a, b, 2005b, 2006). Briefly, rat brains were rapidly
removed and frozen in isopentane at −30°C for 3 min and
kept at –25°C. Coronal sections were cut at 14 μm in a
cryostat (Leitz), placed on gelatinized glass slides, and air-
dried at room temperature for 20 min. Antigens were
localized using the avidin–biotin–peroxidase technique.
Slices were fixed in 4% p-formaldehyde for 15 min and
washed three times with 1× phosphate-buffered saline
(PBS). Endogenous peroxidase activity was quenched with
2% hydrogen peroxide in water (H2O2) for 40 min at room
temperature. Nonspecific binding was blocked for 30 min
at RT in 1× PBS containing 1% bovine serum albumin, 1%
Triton X-100, and 3% normal goat serum. Sections were
then rinsed and incubated overnight either with mouse
monoclonal anti-Myc tag antibody (Abcam, UK; 1:500) to
check for BDNF expression or with rabbit polyclonal anti-
Flag tag antibody (Abcam, UK; 1:500) to check for TrkB
expression. Antibodies were diluted in 1× PBS containing
1% Triton X-100 and 1% normal goat serum. Sections were
then washed three times with 1× PBS and incubated for
45 min at room temperature with the biotinylated secondary
antibodies, either goat anti-mouse immunoglobulin G for
LV-BDNF slices (Vector Laboratories, USA; 1:500) or goat
anti-rabbit immunoglobulin G for LV-TrkB slices (Sigma,
Switzerland; 1:1,000). Sections were rinsed three times for
5 min in 1× PBS at room temperature, followed by incuba-
tion in avidin–biotin complex (Vector Laboratories) in 1×
PBS solution. After three rinses in 1× PBS, all sections
were developed in 0.025% 3,3′-diaminobenzidine-HCl
(DAB) plus 0.02% H2O2 for 10–15 min. Sections were
then dehydrated, mounted in Eukitt permanent medium
(VWR International, Switzerland) and examined with a
Zeiss light microscope.
Statistical analysis
All data were expressed as means±SEM and analyzed
using SPSS v11 software. The general design of locomotor
activity (“Experiment 1”) was a seven-level between-
subjects factor (LV-GFP, LV-BDNF, LV-TrkB, LV-BDNF+
LV-TrkB, LV-TrkT1, LV-TrkB+LV-siRNAs, and LV-BDNF+
LV-TrkB+LV-siRNAs)×repeated measures on the same
subject during 19 days. Drug condition (saline vs. cocaine)
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and doxycycline treatment (session Avs. session B vs. session
C) were added as within-subjects factors. For conditioned-
place preference (“experiment 2”), extinction (“experiment
3”), reinstatement (“experiment 4”) and maintenance of the
CPP after withdrawal (“experiment 5”), a three-level
between-subjects factor (LV-GFP, LV-BDNF and LV-
TrkB)×repeated measures on the same subject during
20 days design was made (within-subjects factor for
extinction). Cocaine treatment during conditioning (5 vs.
20 mg/kg) and doxycycline regimen were considered as
between-subjects factors. Statistical data were analyzed using
an analysis of variance (ANOVA). First, an over-all f test
analysis was performed to identify significant differences
among any of the group means. In case of statistically
significant f ratio scores (p<0.05), a second analysis using
Tukey test has been carried out, where sets of two groups at
a time were compared, to specifically determine significant
differences. Acceptable significance level was set at p<0.05.
Results
Lentivirus expression in HEK293T cells and doxycycline
regulation (data not shown)
Tetracycline-regulatable lentiviruses expressing BDNF
(LV-BDNF) or its receptors TrkB or TrkT1 (LV-TrkB or
LV-TrkT1) were generated (see “Materials and methods”
section). HEK293T cells were infected with different
concentrations of each lentivirus. Transcript levels were
measured by means of qRT-PCR and normalized against β-
actin used as endogenous control. Infection of HEK293T
cells with LV-BDNF induced a titer-dependent expression
of BDNF-specific mRNA. Interestingly, expression of
BDNF also induced a titer-dependent up-regulation of its
receptor TrkB, but not its inactive TrkT1 receptor. Treatment
of infected HEK293T cells with doxycycline (30 ng/mL)
blocked BDNF expression in LV-BDNF-infected cells (as
the virus is tetracycline-regulatable) and also produced a
down-regulation of its corresponding TrkB receptor back to
basal levels (changes are highly significant, p<0.01). Under
these conditions, TrkT1 levels remain unchanged at very low
initial levels of expression. Infection of HEK293T cells with
LV-TrkB or of LV-TrkT1 also induced a titer-dependent
expression of their mRNA, (but no significant expression
of corresponding neurotrophins), which could be blocked
by 30 ng/mL doxycycline. Infection with various titers of
LV-BDNF, LV-TrkB, or LV-TrkT1 did not affect the expres-
sion of β-actin. Co-infection of various titers of LV-BDNF
with another regulatable lentivirus (e.g., LV-CD81 or LV-
urokinase) did not affect expression of the control gene and its
doxycycline-mediated regulation. Similar results were found
with LV-TrkB or LV-TrkT1.
Three siRNAs-expressing lentiviruses, LV-siRNA1, LV-
siRNA2, and LV-siRNA3, targeted against TrkB, have been
generated and tested. HEK293T cells coinfected with LV-
TrkB and LV-siRNA1, LV-siRNA2, or LV-siRNA3 dis-
played a 52%, 30%, and 65% reduction of TrkB mRNA,
respectively, and when co-infected with a mix of all three
silencers (LV-siRNAs), >93% silencing of TrkB mRNA
could be achieved (p<0.01 compared to control cells). LV-
siRNA2 and LV-siRNA3 had no effects on TrkT1 mRNA
expression in HEK293T cells infected with LV-TrkT1,
whereas LV-siRNA1 produced ca. <45% of TrkT1. These
siRNAs-expressing lentiviruses did not affect expression of
other mRNAs, e.g., endogenous β-actin (data not shown).
Experiment 1: cocaine-induced locomotor activity mediated
by overexpression of BDNF and TrkB
Seven groups of lentivirus-infected animals (see “Materials
and methods” section, n=9 per group) were used for
assessing the levels of BDNF or its receptors expression
in the NAc, as measured by qRT-PCR (Figs. 1 and 2). First,
behavioral evaluation was performed in three 5-day
sessions: session A (no doxycycline, enabling full ectopic
gene expression), session B (animals fed doxycycline,
inducing ectopic gene suppression), and then session C
(no doxycycline, recapitulating both gene expression of
session A and initially observed behavior). Statistical
analysis revealed significant interactions between all the
factors: doxycycline × lentivirus (F(12,264)=154.44; p<
0.001), doxycycline × cocaine (F(2,264)=664.26; p<0.001),
cocaine × lentivirus (F(6,132)=674.36; p<0.001), and
doxycycline × cocaine × lentivirus (F(12,264)=125.74; p<
0.005). Chronic cocaine administration was continued daily
throughout each session A, B, and C. This protocol enables
for behavioral evaluation of effects of local gene expression
changes on the very same animals (Bahi et al. 2004a, b,
2005a, b, 2006). A seven-level between-subjects com-
parison revealed a significant effect of groups, indicating
that lentiviral injection has an effect on locomotor activity
(F(39,320)=2898.32; p<0.0001)
When rats were injected with LV-GFP, there was an
interaction between cocaine × doxycycline (F(2,264)=197.14;
p<0.001); within-subjects comparison indicated a significant
effect of the drug, showing that cocaine induces a 6.9-fold
increase in locomotor activity over saline (Fig. 1A and A’;
saline vs cocaine F(2,24)=18.98; p<0.01). Treatment with
doxycycline slightly reduced this activity ratio to 5.7-fold.
By contrast, when rats were injected with LV-BDNF
(cocaine × doxycycline (F(2,264)=433.38; p<0.001), cocaine
induced a 13.6-fold increase in locomotor activity, but this
activation was only 7.5-fold when animals were fed doxy-
cycline in drinking water (F(2,375)=13.699; p<0.001),
turning off expression of ectopic BDNF (Fig. 1B’; within-
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subjects analysis saline vs. cocaine F(2,24)=893.71; p<0.0001).
In addition, in animals injected with LV-TrkB (cocaine ×
doxycycline (F(2,264)=501.11; p<0.001), the locomotor activ-
ity was enhanced by 13.9-fold, but only by approximately 7.5-
fold when fed doxycycline (Fig. 1B’, F(2,24)=893.71; p<
0.0001). When the expression of ectopic BDNF or TrkB
genes was turned on again—upon removing doxycycline from
the drinking water (Fig. 1C’)—cocaine again re-induced
hyperlocomotion and reinstated initially observed levels of
ca. 16.8- and 14.9-fold increase in locomotor activity, respec-
tively (Fig. 1C’; doxycycline treatments F(2,24)=893.71; p<
0.001). These behavioral activities were reflected in mRNA
expression in the NAc (Fig. 2A).
When LV-BDNF is co-injected with LV-TrkB (cocaine ×
doxycycline (F(2,264)=549.24; p<0.001), cocaine-induced
hyperlocomotion is highest, ca. 16-fold higher over saline
(within-subjects comparison saline vs. cocaine F(2,24)=
1,494.86; p<0.0001), but only ca. 7.4-fold when animals
were fed doxycycline (Fig. 1A’ and 1B’; p<0.001).
Removal of doxycycline restored cocaine-induced hyper-
locomotion to its highest level, ca. 20.0-fold over saline
(F(2,24)=1494.86; p<0.001 and p>0.1666 compared to
sessions B and C, respectively). These effects were also
reflected in the doxycycline-dependent expression of
BDNF and TrkB mRNAs (Fig. 2A).
When rats were injected with LV-TrkT1 (cocaine x doxy-
cycline (F(2,264)=14.06; p<0.05), the dominant-negative
form of the Trk receptor, cocaine, induced a slight hyper-
locomotor activity (Fig. 1; 3.9-fold higher than saline in
session A, p<0.001), and doxycycline had a significant
Fig. 2 BDNF, TrkB, and TrkT1 mRNA quantification after locomotor
activity monitoring and doxycycline regulation of transcripts in vivo.
Rats (n=9) were stereotaxically injected into the NAc with the
lentiviral vectors mentioned on the X-axis. Animals were chronically
injected cocaine (15 mg/kg i.p.) under different regimen, i.e., 5 days
without doxycycline (session A); followed by 5 days under doxycy-
cline (session B) and, finally, by 5 days without doxycycline (session
C), and locomotor activity was measured daily. At the end of each
session, three rats per group were sacrificed by decapitation, brains
were removed, and various regions including the NAc were dissected
out. Total RNA was extracted, reverse transcribed, and used for qRT-
PCR using specific primers for BDNF, TrkB and TrkT1 mRNAs. Data
are presented as means±SEM
Fig. 1 BDNF and TrkB induced locomotor activity after saline and
cocaine injections. Locomotor activity was monitored daily as rats
(n=9 per group) were chronically injected, first with saline
(“habituation period”), then, 30 min later, with cocaine–HCl
(15 mg/kg, i.p.). The total horizontal activity is expressed as distance
traveled in cm (mean±SEM) during the three 5-days sessions. In the
first session (a and a′/-doxycycline), rats (n=9 per group) were fed
5% sucrose, then switched to doxycycline regimen during the second
session (b and b′/+ doxycycline) and, finally, changed back to
normal regimen, with doxycycline-free 5% sucrose for the last
session (c and c′/− doxycycline). At the end of each session, three
rats per group were killed *p<0.05, **p<0.01, and ***p<0.005 vs.
saline-treated animals “baseline”; #p<0.05, ##p<0.01 and ###p<
0.005 vs. LV-GFP-infected animals; £ p<0.05, ££ p<0.01, and £££
p<0.005 vs. LV-TrkB-infected animals; $p<0.05, $$p<0.01 and
$$$p<0.005 vs. LV-BDNF+LV-TrkB infected animals; Ø p<0.05,
ØØ p<0.01 and ØØØ p<0.005 vs. water fed animals
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behavioral effect (Fig. 1B; within-subjects comparison of
doxycycline treatments F(2,24)=72.40; p<0.0001), and it
affected the expression level of TrkT1 mRNA (Fig. 2A).
No difference was observed between sessions A and C
(F(2,24)=72.40; p>0.938). Overexpression of TrkT1 did not
affect the expression of BDNF or TrkB mRNA (Fig. 2A).
Animals co-injected with LV-TrkT1 and LV-BDNF also
induced a low response to cocaine, similar to GFP-treated
animals, which was almost unchanged by doxycycline (data
not shown).
In vivo silencing of TrkB The effects of silencing TrkB on
BDNF signaling in the NAc was also tested on separate
groups (Figs. 1 and 2). Animals co-injected with LV-GFP
and LV-TrkB-siRNAs (cocaine × doxycycline (F(2,264)=
330.33; p<0.001) showed slightly lower levels in cocaine-
mediated hyperlocomotion over LV-GFP controls, probably
due to inhibition of endogenous TrkB (data not shown).
However, when animals were co-injected with LV-TrkB
and LV-TrkB-siRNAs (cocaine × doxycycline; F(2,264)=
197.14; p<0.001), cocaine induced ca. a 9.6-fold increase
in hyperlocomotor activity over saline (Fig. 1; within-
subjects comparisons saline vs. cocaine F(2,24)=1022.03;
p<0.0001) that could be blocked by doxycycline reversibly
(Fig. 1; within-subjects comparisons of doxycycline treat-
ment: sessions A and C vs. session B: F(2,24)=1022.03; p<
0.0001; session A vs. session C: p>0.056). This cocaine-
mediated increased hyperlocomotion is much smaller than
in the absence of the LV-TrkB-siRNAs (p<0.01) because
the siRNA-expressing lentivirus also suppresses the expres-
sion of the endogenous TrkB (Fig. 2A) and part of the
observed hyperlocomotion was mediated by cocaine up-
regulation of TrkB in the NAc. Doxycycline reversibly
blocked BDNF- or TrkB-mediated hyperlocomotion
(Fig. 1B’ and C’). An interesting observation must also be
noted, namely, the fact that silencing TrkB also induced a
down-regulation of the endogenous BDNF expression in
the NAc (compare BDNF mRNA expression, Fig. 2).
When LV-TrkB-siRNAs was co-injected with LV-TrkB
together with LV-BDNF, similar behavioral effects were
observed (cocaine × doxycycline (F(2,264)=177.86; p<0.001),
(Fig. 1; within subjects comparison saline vs. cocaine F(2,24)=
206.74; p<0.0001). The effects were of similar amplitude
and were doxycycline regulated in a reversible way (Fig. 1;
within-subjects comparisons of doxycycline treatment:
sessions A and C vs. sessions B: F(2,24)=206.74; p<0.01;
session A vs. session C: p>0.924). However, when co-
injected with LV-TrkT1, slightly lower levels in cocaine-
mediated hyperlocomotion over LV-GFP controls were
observed because of inhibition of endogenous TrkB, but this
was not affected by doxycycline.
Experiment 2: LV-BDNF- and LV-TrkB-induced
conditioned-place preference
Animals (n=9 per group) were injected with either LV-GFP,
LV-BDNF, or LV-TrkB into the NAc and trained for
conditioned-place preference using 5 or 20 mg/kg of
cocaine. The pre-exposure test showed that animals spent
an equal amount of time in the two different chambers.
Repeated ANOVA for both chambers (wire grid, floor
mesh) revealed no significant effect (between-subjects
factor comparisons, wire grid vs. floor mesh: F(11,60)=
0.733; p>0.396); thus, the test was unbiased in terms of
chamber preferences of untreated animals. Nevertheless,
between-subjects comparisons revealed an effect of lenti-
viral vector used (F(11,60)=68.772; p<0.0001).
Figure 3 shows the results of the CPP test. Animals
displayed significant place preference over the GFP-treated
control and spent markedly more time into the cocaine-
Fig. 3 LV-BDNF and LV-TrkB enhance cocaine-induced-place
preference. Four sets of three groups of rats (n=9 per group) were
injected with either LV-GFP, LV-BDNF, or LV-TrkB. Rats were then
trained for conditioned-place preference using 5 mg/kg of cocaine (a)
or 20 mg/kg of cocaine (b; see “Materials and Methods” section). One
set of each (six groups, n=9 per group) was given 0.02% doxycycline
in 5% sucrose during the conditioning period to block gene expression
during learning. The other sets were fed 5% sucrose only, allowing
full expression of both BDNF and TrkB. After conditioning, rats were
tested at day 10, and the time spent in cocaine-paired box was
monitored. Values indicate means±SEM. *p<0.05 compared to LV-
GFP; #p<0.05 ##p<0.01 compared to animals injected 5 mg/kg
during conditioning; £ p<0.05 ££ p<0.01 compared to rats with no
doxycycline during the conditioning (learning) period
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paired box (F(11,60)=68.722; p<0.0001). The time increase
spent into cocaine-paired chamber was related to the dose
of drug administered. Between-subjects comparisons for
cocaine dose during acquisition indicate a significant dose
effect (Fig. 3A; 5 mg/kg vs. 20 mg/kg F(1,70)=24.955, p<
0.001), corresponding to ca. 24% increase at low dose
(Fig. 3A; within subjects comparisons, saline vs. cocaine
at 5 mg/kg: F(5,30)=14.39; p<0.005) and 53% increase at
higher dose (Fig. 3B; saline vs. cocaine at 20 mg/kg: F(5,30)=
106.38; p<0.0001). During conditioning (days 3–10), some
groups were fed 0.02% doxycycline in 5% sucrose to block
ectopic gene expression. Between-subjects comparisons for
doxycycline feeding during acquisition indicated a strong
and significant effect (F(1,70)=24.704, p<0.001). Under these
conditions, no place preference was observed, compared to
controls (F(2,15)=0.22; p>0.842), even at high dose of
cocaine (F(2,15)=0.68; p>0.491).
Experiment 3: extinction by repeated testing
In another series of experiments, animals underwent a
prolonged period of withdrawal from cocaine for 20 days
without injections, following the establishment of CPP
(Fig. 4). Under these conditions, time spent in cocaine-
paired box was gradually diminishing over testing days,
and within-subjects comparisons of extinction revealed sig-
nificant differences (extinction session 1 to 20: F(11,60)=
76.447; p<0.001). Animals treated with LV-BDNF or LV-
TrkB (Fig. 4B and C) clearly displayed marked delayed
extinction over LV-GFP control animals (Fig. 4A; between-
subjects comparisons, LV-BDNF, and LV.TrkB vs. LV-GFP:
F(2,15)=30.12; p<0.01). Again, delayed extinction was
dose-dependent and was very pronounced at high dose of
cocaine (between subjects factor, 5 mg/kg vs. 20 mg/kg:
F(5,36)=163.59; p<0.0001). However, if animals had been
fed doxycycline during acquisition (days 3–9 of the CPP
protocol), preventing ectopic gene expression, no signifi-
cant difference with LV-GFP-treated animals could be
observed, even at a high dose of cocaine (Fig. 4A’, B’
and c’; between-subjects factor, with vs. without doxycy-
cline: F(4,31)=1.06; p>0.394). Furthermore, at the end of
the extinction process, there was no difference among all
the groups (three-level between-subjects comparisons, LV-
GFP vs. LV-BDNF vs. LV-TrkB: F(11,60)=0.55; p>0.858).
This observation prompted us to proceed towards priming
assessments.
Experiment 4: reinstatement by priming using low
dose of cocaine
At the end of the period of withdrawal from cocaine
(experiment 3), animals received saline injections or
cocaine priming with low dose of cocaine (2 mg/kg;
Fig. 5). Under these conditions, within-subjects saline
priming did not affect CPP score (Fig. 5A and B; F(11,60)=
0.39; p>0.956). In contrast, priming with very low dose of
cocaine (2 mg/kg) at the end of this 20-day withdrawal
period induced full recovery of place preference for animals
treated with high doses of cocaine during the conditioning
period (Fig. 5B’; within subject saline vs. cocaine: F(11,60)=
Fig. 4 LV-BDNF and LV-TrkB-mediated delayed extinction of
cocaine-induced-place preference. Four sets of three groups of rats
(n=9 per group) were injected either with LV-GFP (a), LV-BDNF (b),
or LV-TrkB (c). Rats were trained for conditioned-place preference as
in Fig. 3. During the conditioning period only, one set of each (six
groups, n=9 per group) was fed 5% sucrose (a, b, and c), and the
other sets were fed 5% sucrose supplemented with 0.02% doxycycline
(a′, b′ and c′). After CPP monitoring on day 10, rats were fed 5%
sucrose only and were placed daily into the setup for 20 min during
20 days, but no injections were given during this prolonged period of
withdrawal from cocaine. Values indicate means±SEM. The SEM
bars have been omitted from the points for clarity
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90.60; p<0.001). Between-subjects comparisons showed
that animals receiving low dose of drug (5 mg/kg vs.
20 mg/kg cocaine during acquisition: F(1,70)=44.33; p<
0.001) and no doxycycline during acquisition (with vs.
without doxycycline: F(1,70)=18.35; p<0.001) still dis-
played slight but significant recovery of place preference
upon priming after this 20-day period (Fig. 5A’). Animals
fed doxycycline during the acquisition period, i.e., when
gene expression had been blocked during learning, dis-
played no place preference upon cocaine priming (Fig. 5A’;
between-subjects comparison, 5 mg/kg during acquisition:
F(2,15)=0.299; p>0.746). In contrast, animals previously
conditioned with 20 mg/kg of cocaine displayed highly
significant CPP scores upon cocaine priming (Fig. 5B’;
between-subjects comparison, 20 mg/kg during acquisition:
F(2,15)=130.62; p<0.001).
Experiment 5: maintenance of the CPP
In another series of experiments, animals have been trained
for CPP, then kept in their home cages for 5 weeks without
drug injection (Fig. 6). At the end of this period, place
Fig. 5 Extinction with saline pairings and reinstatement with low
dose of cocaine injection. Four sets of three groups of rats (n=9 per
group) were injected with either LV-GFP, LV-BDNF, or LV-TrkB. Rats
were then trained for conditioned-place preference with 5 mg/kg of
cocaine (a and a′) or 20 mg/kg of cocaine (b and b′). During the
conditioning period only, one set of each (six groups, n=9 per group)
was fed 5% sucrose only, and the other sets were fed 5% sucrose and
0.02% doxycycline as in Fig. 4. After CPP monitoring on day 10, all
animals were fed 5% sucrose only, and saline injections paired with
each chamber alternately were performed once a day for 10 days.
Place preference was then monitored (a and b). The next day, all
animals received a priming injection of cocaine (2 mg/kg, i.p.), and
place preference was immediately monitored again (a′ and b′). Values
indicate means±SEM. *p<0.05 compared to LV-GFP; #p<0.05 ##p<
0.01 compared to animals injected 5 mg/kg during conditioning; £ p<
0.05 ££ p<0.01 compared to animals with no doxycycline during the
conditioning (learning) period; $ p<0.05 $$ p<0.01 $$$ p<0.005
compared to animals receiving 2 mg/kg of cocaine for priming
Fig. 6 LV-BDNF and LV-TrkB maintained cocaine-induced-place
preference. Four sets of three groups of rats (n=9 per group) were
injected with either LV-GFP, LV-BDNF, or LV-TrkB. Rats were then
trained for conditioned-place preference, with 5 mg/kg of cocaine (a)
or 20 mg/kg of cocaine (b), fed with or without doxycycline in 5%
sucrose, as in Figs. 4 and 5 above. After CPP monitoring on day 10,
rats were kept in their home cages for 5 weeks. Thereafter, place
preference was monitored. Values indicate means ± SEM. * p<0.05
compared to LV-GFP; # p<0.05 compared to 20 mg/kg injected rats
during conditioning; £ p<0.05 compared to rats with no doxycycline
during the conditioning (learning) period
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preference was monitored without drug injection. Interest-
ingly, place preference was maintained upon a prolonged
period of withdrawal from cocaine (three-level between-
subjects factor: F(2,15)=38.33; p<0.001). Between-subjects
comparison of the initial CPP test showed that animals
treated with high dose of cocaine spent more time in the
cocaine-paired chamber when using 20 mg/kg during
conditioning (Fig. 6B; between-subjects comparisons, 5
vs. 20 mg/kg: F(1,70)=7.85; p<0.007). The enhanced CPP
score was observed only if ectopic gene expression was
possible during the learning period (between-subjects
comparison of doxycycline treatment: F(1,70)=13.53; p<
0.004). Indeed, animals fed doxycycline during acquisition,
i.e., when ectopic gene expression had been blocked at this
period, displayed no place preference (Fig. 6A and B;
within-subjects comparison of doxycycline treatment:
F(2,15)=0.14; p>0.872). CPP reinstatement did not occur
in all groups that have received doxycycline during
acquisition, and no statistical difference was observed
between LV-GFP, LV-BDNF, or LV-TrkB-infected animals
(three-level between-subjects comparison of doxycycline
treatments: F(5,30)=0.76; p>0.585). It should be mentioned
that between-subjects comparisons of post-conditioning and
reinstatement showed that there was a slight but significant
difference between CPP scores during post-conditioning
and reinstatement (Fig. 3 vs. Fig. 6; F(23,120)=71.066; p<
0.005).
At the end of behavioral analysis, animals have been
sacrificed and gene expression assessed by means of
immunohistochemistry (Fig. 7 and supplementary Figure
S1). As expected, behavioral changes fully correlate
lentivirus-mediated expression changes of BDNF or TrB.
Animals infected with LV-BDNF and LV-TrkB displayed
high expressions of BDNF or TrkB in the infected brain
area (NAc), which was almost completely suppressed when
the animals were fed doxycycline.
Discussion
In this study, we have developed an approach enabling a
thorough investigation of the role of BDNF in cocaine-
induced behavior, in a way that is superior to previous
genetic and pharmacological methods. The use of regulat-
able lentiviruses locally overexpressing either BDNF or its
receptors TrkB or TrkT1 in combination enables to test on
the very same animal the effects of very local changes in
gene expression on behavior. In combination with lentivi-
ruses locally silencing these genes, it enabled for the first
time a very clear evaluation of the role of BDNF expression
in the NAc in cocaine reward. Our data demonstrate that
transient overexpression of BDNF and/or its receptor TrkB
in the mesolimbic DA pathway induces potent and long-
lasting behavioral effects. Intra-NAc BDNF or TrkB
expression increased locomotor activity and resulted into
the development of behavioral sensitization together with
enhanced cocaine-induced place preference. In contrast,
animals receiving lentiviral injection of TrkT1 or TrkB-
specific siRNAs were less sensitive to the locomotor
stimulant effects of cocaine than TrkB-treated animals.
Furthermore, BDNF and TrkB are involved in the learning
of drug preference, and this acquisition is maintained
throughout after a prolonged period of withdrawal from
cocaine, but only if BDNF expression is reactivated. This
confirms studies showing that BDNF is important in
Fig. 7 BDNF and TrkB immunohistochemistry at the site of
stereotaxic injection of LV-BDNF or LV-TrkB in the nucleus
accumbens (NAc). a Rats were killed at the end of the experiment,
brains were dissected out and processed for immunohistochemistry
(see “Materials and Methods” section for details). Magnification ×40.
b Topography of stereotaxic injection sites. Antero-posterior coor-
dinates according to Paxinos and Watson (1998), are shown on the left
side of each coronal section. cc Corpus callosum, Co NAc core, CPu
caudate putamen, Sh NAc shell
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regulating synaptic plasticity in the brain areas that process
reward information and that BDNF in the NAc promotes
persistent cocaine-seeking behaviors and heightens relapse
vulnerability (Schoenbaum et al. 2007).
Four major findings arise from cocaine-induced CPP
experiments. First, these data show that cocaine-induced
CPP was enhanced by BDNF and TrkB, and once estab-
lished, CPP was maintained for at least 5 weeks compared
to GFP-injected animals. Second, the conditioned-place
preference could be extinguished by repeated testing for the
place preference without drug exposure. However, this
extinction was delayed when animals were overexpressing
BDNF or TrkB in the mesolimbic DA system. Finally, and
most importantly, our data show that, after extinction, a
priming injection with low dose of cocaine (2 mg/kg)
reinstated the cocaine-induced CPP. After a prolonged
period of withdrawal from cocaine, animals given an
injection of cocaine before the test session spent more time
in the chamber originally paired with cocaine during the
conditioning phase. Reinstatement after extinction was
enhanced when animals were stereotaxically injected with
LV-BDNF or LV-TrkB in the NAc. Furthermore, CPP scores
were highly reduced if animals were fed doxycycline during
the acquisition period; therefore, when BDNF and TrkB
were inhibited during learning, animals had greater difficul-
ties to associate cocaine injections with a specific environ-
mental context.
Our data clearly support previous observations and
further establish that BDNF modulates behavior and reward
during the acquisition of cocaine CPP. BDNF and TrkB
are involved in appetite behavior (Kernie et al. 2000);
therefore, it is not surprising that overexpression of BDNF
activates brain reward and place preference in a CPP test.
Furthermore, we show that upon BDNF expression,
extinction is delayed, which stresses the significant impli-
cations for BDNF signaling in cocaine reward. The
rewarding effects of cocaine assessed in the CPP paradigm
and open-field locomotor activity monitoring are drastically
and reversibly attenuated in TrkB-silenced animals and
confirm important roles for BDNF in psychostimulant
actions. This agrees with observations on BDNF knockout
mice (Sora et al. 2001). Heterozygous BDNF knockout
mice displayed less locomotion during habituation and less
locomotion after cocaine injections. Cocaine-CPP was
reduced in the BDNF heterozygotes mice, which displayed
no significant difference from saline control values at a
dose of 10 mg/kg s.c. cocaine, although they exhibited
cocaine-induced preference at a 20 mg/kg dose. However,
developmentally related behavioral impairment and particu-
larly learning deficits could not be excluded in knockout
models—and indeed have been documented in BDNF+/−
mice—which is not the case in the lentiviral approach
proposed in this study.
The finding that CPP, once established, was maintained
over time is interesting. Our findings clearly demonstrate
that drug-related cues are still effective over 5 weeks,
implying that BDNF and TrkB may facilitate memory
consolidation. This agrees with previous reports showing
that cocaine-induced CPP is maintained up to 4 weeks
(Mueller and Stewart 2000). In another study, conditioned-
place preference based on pairing an environment with
either morphine or naloxone has been reported to occur
after three pairings of subcutaneous drug injections and to
be retained for at least 1 month (Mucha and Iversen 1984).
In addition, our data show that a prolonged period of
withdrawal from cocaine led to the reduction of the CPP
score. This fully agrees with published results from other
groups (Mueller and Stewart 2000), showing that once
cocaine-induced CPP has been established, rats injected
only with saline subsequently display significant attenua-
tion in cocaine-induced increase in time spent, in com-
parison to non-extinction-treated control rats (Calcagnetti
and Schechter 1993).
The changes observed in the CPP paradigmwere strikingly
similar to the effects of TrkB knockout on cocaine-induced
locomotion (Grimm et al. 2003; Hall et al. 2003; Horger et al.
1999). Locomotor stimulating effects of cocaine were
reduced but not eliminated in TrkB-silenced animals with a
similar dose–effect profile. TrkB silencing produces a down-
regulation of endogenous BDNF, again emphasizing the
striking role of the BDNF system on cocaine-mediated
behavioral changes. Decreases in cocaine efficacy with
reduced BDNF or TrkB expression are consistent with
observations that cocaine sensitization is delayed in the
BDNF +/− mice (Hall et al. 2003) and with observations that
BDNF administration delays extinction (Grimm et al. 2003)
and enhances cocaine sensitization and conditioned re-
inforcement (Horger et al. 1999). Together, this strengthens
the notion that differences in BDNF expression may underlie
associations between markers near the BDNF gene locus and
drug addiction and supports suggestions that human allelic
variation at a locus in or near the BDNF gene could con-
tribute to individual differences in human addiction vulner-
ability (Krebs et al. 2000; Uhl et al. 2001). Human genomic
markers within or near the BDNF locus have been linked to
or associated with substance abuse (Hall et al. 2003). Post
mortem human brain specimens reveal individual differ-
ences in the levels of BDNF mRNA and in mRNA splicing
patterns.
However, these previous works did not address two
important questions. What is the role of BDNF in cocaine
reward and relapse, and in which brain area(s) does BDNF
have its effects on cocaine reward and relapse? The present
study has been performed into the NAc shell, thus sup-
porting the view that behavioral sensitization may involve
BDNF or TrkB expression changes preferentially in this
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brain area. In the shell, but not in the core of the NAc, the
level of BDNF mRNA is significantly increased after acute
and repeated cocaine treatment, and during cocaine with-
drawal (Filip et al. 2006). Combined knockouts of DAT and
SERT genes are required to eliminate cocaine reward (Sora
et al. 2001). As BDNF effects on both systems have been
identified (Hyman et al. 1991, 1994), the large effects of
partial TrkB knockdown on cocaine reward mechanisms
might also be largely because of actions of BDNF on both
dopaminergic and serotoninergic systems (Altar et al.
1994). This may thus support the idea that both neuro-
transmitter functions may be critical determinants of
cocaine reward (Hall et al. 2003; Uhl et al. 2002). To
confirm that BDNF had a critical role in the NAc shell, as
opposed to upstream or downstream structures, Graham
locally injected an adeno-associated viral vector to knock-
down BDNF protein production in the accumbens shell,
leading to a substantial reduction in BDNF levels in this
brain area (46%) and causing a downward shift in the dose–
response curve, suggesting a decrease in cocaine’s reward-
ing effects (Graham et al. 2007). Our present experiments
clearly consolidate these suggestions and identifies the
BDNF gene together with its active TrkB receptor because
of their mutual individual variations and mutual regulatory
effects in the NAc, as an essential gene for cocaine reward
and cocaine addiction.
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